Evidence method
Level · gp.fundamentals.capex_revenue_ratio
10.79% · OPTIONAL · VALID
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME
ANIK · Mar 31, 2025
Anika Therapeutics, Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.
STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration
State dimensions
Filing0001171843-25-003019General Corporate
Evidence method
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
-0.50% · OPTIONAL · VALID
Evidence method
Yoy · gp.fundamentals.revenue
-35.42% · CORE · NOT_ENOUGH_HISTORY
Evidence method
Level · gp.fundamentals.inventory_revenue_ratio
81.53% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.gross_margin
56.10% · CORE · VALID
Evidence method
Level · gp.fundamentals.operating_margin
-16.37% · CORE · VALID
Evidence method
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
23.15% · OPTIONAL · VALID
Evidence method
Level · gp.fundamentals.sbc_revenue_ratio
10.94% · OPTIONAL · VALID
As-filed lineage
Fundamental state history
Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History15 statesHistory building
Dec 31, 20220/7 normalizedLevel 3Mar 31, 20230/7 normalizedLevel 3Jun 30, 20230/7 normalizedLevel 3Sep 30, 20230/7 normalizedLevel 3Dec 31, 20230/8 normalizedLevel 3Mar 31, 20240/8 normalizedLevel 3Jun 30, 20240/8 normalizedLevel 3Sep 30, 20240/8 normalizedLevel 3Dec 31, 20247/8 normalizedLevel 3Mar 31, 20257/8 normalizedLevel 3Jun 30, 20257/8 normalizedLevel 3Sep 30, 20256/7 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 3
Period transition
What moved in the state?
- Previous
- 6.45%
- Current
- 10.79%
- Delta
- 4.34%
- Previous
- 4.51%
- Current
- -0.50%
- Delta
- -5.00%
- Previous
- -28.05%
- Current
- -35.42%
- Delta
- -7.37%
- Previous
- 19.86%
- Current
- 81.53%
- Delta
- 61.68%
- Previous
- 63.38%
- Current
- 56.10%
- Delta
- -7.28%
- Previous
- -4.25%
- Current
- -16.37%
- Delta
- -12.12%
- Previous
- 21.30%
- Current
- 23.15%
- Delta
- 1.85%
- Previous
- 10.95%
- Current
- 10.94%
- Delta
- -0.01%
Self-history only
Previous similar states
Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research
Transitioned To · ANIK Fundamental State →Has State · Anika Therapeutics, Inc. →Transitioned To · ANIK Fundamental State →Transitioned To · ANIK CAPEX_INTENSITY_INCREASED →Transitioned To · ANIK CASH_GENERATION_DECREASED →Transitioned To · ANIK GROWTH_DECREASED →Transitioned To · ANIK INVENTORY_PRESSURE_INCREASED →Transitioned To · ANIK MARGIN_DECREASED →Transitioned To · ANIK PROFITABILITY_DECREASED →Transitioned To · ANIK R_AND_D_INTENSITY_INCREASED →Transitioned To · ANIK SBC_INTENSITY_DECREASED →
Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.